Spots Global Cancer Trial Database for erlotinib
Every month we try and update this database with for erlotinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme | NCT00672243 | Glioblastoma Gliosarcoma | Erlotinib + sir... | 18 Years - | Duke University | |
| Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer | NCT00380029 | Bladder Cancer | Erlotinib Radical Cystect... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) | NCT00600496 | Breast Cancer Breast Neoplasm... Colon Cancer Colonic Cancer Colon Neoplasms Lung Cancer Melanoma Kidney Cancer | AZD6244 Dacarbazine Erlotinib Docetaxel Temsirolimus | 18 Years - 130 Years | AstraZeneca | |
| Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | NCT03297606 | Lymphoma, Non-H... Multiple Myelom... Advanced Solid ... | Olaparib Dasatinib Nivolumab plus ... Axitinib Bosutinib Crizotinib Palbociclib Sunitinib Temsirolimus Erlotinib Trastuzumab plu... Vemurafenib plu... Vismodegib Tucatinib | 18 Years - | Canadian Cancer Trials Group | |
| Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) | NCT01182350 | Diffuse Intrins... | Bevacizumab Erlotinib Temozolomide Radiation | 3 Years - 18 Years | Dana-Farber Cancer Institute | |
| BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC) | NCT01562028 | Lung Cancer | Erlotinib Bevacizumab | 18 Years - | ETOP IBCSG Partners Foundation | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| 2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC) | NCT00835471 | Carcinoma, Non-... | erlotinib plus ... erlotinib | 18 Years - | Dutch Society of Physicians for Pulmonology and Tuberculosis | |
| Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | NCT00522938 | Carcinoma, Non-... | CHR-2797 (tosed... erlotinib | 18 Years - | Chroma Therapeutics | |
| Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca | NCT01555489 | Stage IV Pancre... | Ascorbic Acid | 18 Years - | Thomas Jefferson University | |
| Erlotinib and Sunitinib in NSCLC | NCT00581789 | Non Small Cell ... | erlotinib, suni... | 18 Years - | University of Wisconsin, Madison | |
| Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial (SELECT) | NCT00462995 | Non Small Cell ... | Erlotinib Erlotinib | 18 Years - 95 Years | University Health Network, Toronto | |
| Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. | NCT01652469 | Carcinoma, Non-... | Erlotinib Docetaxel | 18 Years - | ETOP IBCSG Partners Foundation | |
| Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC | NCT00997334 | Non-small Cell ... | Erlotinib | 18 Years - | Dana-Farber Cancer Institute | |
| Ph I Dasatinib + Erlotinib in Recurrent MG | NCT00609999 | Glioblastoma Gliosarcoma | Erlotinib and D... | 18 Years - | Duke University | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer | NCT01967095 | EGFR-Mutant Lun... | erlotinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer | NCT02694536 | Pancreatic Canc... | Erlotinib Gemcitabine | 18 Years - | Hoffmann-La Roche | |
| Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy | NCT01186861 | Non-Small Cell ... | OSI-906 erlotinib placebo | 18 Years - | Astellas Pharma Inc | |
| Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer | NCT00614653 | Pancreatic Canc... | Bevacizumab Erlotinib Capecitabine Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation | NCT01683175 | Non-small Cell ... | Erlotinib cis-platinum Vinorelbine | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC | NCT00410059 | Lung Cancer | Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Erlotinib in Combination With Bortezomib | NCT00895687 | Advanced Cancer | Erlotinib Hydro... Bortezomib | - | M.D. Anderson Cancer Center | |
| Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma | NCT01851096 | Cancer | SNX-5422 | 18 Years - | Esanex Inc. | |
| Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer | NCT00473083 | Rash | Minocycline Clindamycin 2% ... Erlotinib Topical clindam... | 18 Years - | British Columbia Cancer Agency | |
| Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors | NCT00520013 | Ovarian Cancer Fallopian Tube ... Primary Periton... Papillary Serou... Clear Cell Mull... | bevacizumab erlotinib paclitaxel carboplatin | 18 Years - | Dana-Farber Cancer Institute | |
| Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma | NCT01752205 | Esophageal Squa... | Paclitaxel Erlotinib Radiation thera... | 18 Years - | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | |
| IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer | NCT00300586 | Stage IV Non-sm... | observation gemcitabine erlotinib | 18 Years - 70 Years | Hospices Civils de Lyon | |
| Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer | NCT00543842 | Rectal Cancer | Bevacizumab Capecitabine Erlotinib Radiation Thera... Surgery | 18 Years - | M.D. Anderson Cancer Center | |
| Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer | NCT00281021 | Carcinoma, Non-... | Erlotinib plus ... | 18 Years - | University of Louisville | |
| Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation | NCT01683175 | Non-small Cell ... | Erlotinib cis-platinum Vinorelbine | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer | NCT02034097 | Cancer | Foretinib Erlotinib | 18 Years - | GlaxoSmithKline | |
| MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer | NCT00769483 | Pancreatic Canc... Pancreatic Aden... | MK-0646 Gemcitabine Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas | NCT00532441 | Hepatocellular ... | Erlotinib Docetaxel | 18 Years - | Hoosier Cancer Research Network | |
| Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer | NCT01389440 | Pancreatic Aden... | Gemcitabine and... | 18 Years - 75 Years | Grupo Espanol Multidisciplinario del Cancer Digestivo | |
| Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC) | NCT00955149 | Primary Scleros... Trisomy 7 Cholangiocarcin... Chemoprevention | Erlotinib (Tarc... | 18 Years - | Mayo Clinic | |
| Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck | NCT01116336 | Cancer of Head ... Neoplasms, Head... | Erlotinib Green Tea Polyp... | 18 Years - | Emory University | |
| Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC) | NCT00826449 | Lung Cancer Non-Small Cell ... | Dasatinib Erlotinib | 16 Years - | M.D. Anderson Cancer Center | |
| Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver | NCT02273362 | Cirrhosis Hepatocellular ... | Erlotinib Erlotinib Hydro... Laboratory Biom... Quality-of-Life... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer | NCT00452413 | Non-Small Cell ... Malignant Solid... | enzastaurin erlotinib | 18 Years - | Eli Lilly and Company | |
| Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors | NCT00998036 | Triple Negative... | Temsirolimus Cisplatin Erlotinib | 18 Years - | Columbia University | |
| Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer | NCT00380029 | Bladder Cancer | Erlotinib Radical Cystect... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors | NCT00692640 | Cancer Non-small Cell ... | XL147 (SAR24540... Erlotinib | 18 Years - | Sanofi | |
| Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver | NCT02273362 | Cirrhosis Hepatocellular ... | Erlotinib Erlotinib Hydro... Laboratory Biom... Quality-of-Life... | 18 Years - | National Cancer Institute (NCI) | |
| The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment | NCT01796288 | Non Small Cell ... | simultaneous ra... Erlotinib | 18 Years - 80 Years | Wu Jieping Medical Foundation | |
| Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer | NCT00739063 | Breast Cancer | Tarceva | - | M.D. Anderson Cancer Center | |
| Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL) | NCT00391248 | Non-small Cell ... | Erlotinib | 18 Years - | Ontario Clinical Oncology Group (OCOG) | |
| Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer | NCT00834678 | Breast Cancer | bendamustine erlotinib Maintenance erl... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer | NCT00393068 | Esophageal Canc... | Erlotinib Bevacizumab Paclitaxel Carboplatin 5-FU Radiation thera... Surgery | 18 Years - | SCRI Development Innovations, LLC | |
| A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | NCT00947167 | Neuroendocrine ... Carcinoid Tumor... Adrenal Gland T... Neuroblastoma Pancreatic Neur... Multiple Endocr... | pertuzumab erlotinib | - | Stanford University | |
| Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer | NCT01303029 | Metastatic Panc... | Gemcitabine+erl... Gemcitabine+erl... | 18 Years - | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | |
| Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma | NCT00791544 | Liver Carcinoma | AVE1642 sorafenib erlotinib | 18 Years - | Sanofi | |
| Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug) | NCT01299220 | Skin Rash | Acitretin | 18 Years - | University of Pittsburgh | |
| Study of Erlotinib in Combination With Bortezomib | NCT00895687 | Advanced Cancer | Erlotinib Hydro... Bortezomib | - | M.D. Anderson Cancer Center | |
| Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma | NCT01565538 | Lung Cancer | Erlotinib Pemetrexed | 18 Years - 75 Years | Sun Yat-sen University | |
| Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer | NCT00810719 | Pancreatic Canc... | Erlotinib gemcitabine | 18 Years - | University of California, Davis | |
| A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | NCT00947167 | Neuroendocrine ... Carcinoid Tumor... Adrenal Gland T... Neuroblastoma Pancreatic Neur... Multiple Endocr... | pertuzumab erlotinib | - | Stanford University | |
| A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations | NCT01342965 | Non-Small Cell ... | Erlotinib Chemotherapy | 18 Years - | Hoffmann-La Roche | |
| Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers | NCT00738751 | Lung Cancer Head and Neck C... | Panobinostat (L... erlotinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Erlotinib in Combination With Dasatinib | NCT00895128 | Advanced Cancer | Erlotinib Hydro... Dasatinib | 18 Years - | M.D. Anderson Cancer Center | |
| Individualized Drug Treatment for Treating Patients With Pancreatic Cancer | NCT00276744 | Pancreatic Canc... | cetuximab capecitabine docetaxel Erlotinib Gemcitabine Irinotecan mitomycin C rapamycin conventional su... | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer | NCT00448240 | Head and Neck C... Carcinoma, Squa... | Erlotinib | 18 Years - | Henry Ford Health System | |
| SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716) | NCT00732810 | Breast Neoplasm... Carcinoma, Non-... | SCH 727965 Capecitabine Erlotinib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer | NCT00983307 | Carcinoma, Non-... | Erlotinib Hypofractionate... | 18 Years - | Thomas Jefferson University | |
| Elderly Independent Patients With Non Small Cell Lung Cancer (NSCLC) | NCT00418704 | Non Small Cell ... | Erlotinib taxotere | 65 Years - | Groupe Francais De Pneumo-Cancerologie | |
| A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone | NCT00457392 | Carcinoma, Non-... | erlotinib sunitinib erlotinib placebo | 18 Years - | Pfizer | |
| Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma | NCT00791544 | Liver Carcinoma | AVE1642 sorafenib erlotinib | 18 Years - | Sanofi | |
| A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER) | NCT01378962 | Non-Squamous No... | erlotinib | 18 Years - | Hoffmann-La Roche | |
| Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme | NCT00672243 | Glioblastoma Gliosarcoma | Erlotinib + sir... | 18 Years - | Duke University | |
| Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... | NCT01229150 | Non Small Cell ... | AZD6244 Erlotinib AZD6244 + Erlot... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma | NCT01032070 | Recurrent or Re... | erlotinib etoposide | 1 Year - 21 Years | Astellas Pharma Inc | |
| A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) | NCT00600496 | Breast Cancer Breast Neoplasm... Colon Cancer Colonic Cancer Colon Neoplasms Lung Cancer Melanoma Kidney Cancer | AZD6244 Dacarbazine Erlotinib Docetaxel Temsirolimus | 18 Years - 130 Years | AstraZeneca | |
| Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site | NCT00737243 | Carcinoma | Paclitaxel Carboplatin Bevacizumab Erlotinib Treatment deter... | 18 Years - | SCRI Development Innovations, LLC | |
| Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC | NCT00522249 | Carcinoma, Rena... | Pegylated Alfa ... sunitinib erlotinib | 18 Years - | The Methodist Hospital Research Institute | |
| EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas | NCT01257594 | Brain Cancer | erlotinib Cytoreductive S... | 18 Years - | Columbia University | |
| Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer | NCT00367601 | Lung Cancer | Erlotinib Bevacizumab | 18 Years - | Hoosier Cancer Research Network | |
| Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma | NCT01198028 | Metastatic Skin... Recurrent Skin ... | Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II | NCT05525858 | Solid Tumor Advanced Solid ... Metastatic Canc... | Alectinib Atezolizumab Erlotinib Trastuzumab + P... Trastuzumab emt... Vemurafenib Bevacizumab + E... Entrectinib Pralsetinib | 19 Years - | Seoul National University Bundang Hospital | |
| Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib | NCT00609804 | Non-Small Cell ... | Sorafenib Erlotinib | 18 Years - | SCRI Development Innovations, LLC | |
| A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen | NCT00769067 | Non-small Cell ... | Erlotinib PF-00299804 | 18 Years - 99 Years | Pfizer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
